The Finnish company Aidian develops, manufactures and sells instruments and tests that are used in such fields as primary care to provide quick and accurate test results. Aidian’s range of tests addresses several global health problems, such as antimicrobial resistance (AMR), diabetes and colorectal cancer. Aidian has tests that are intended to reduce unnecessary prescriptions of antibiotics, which is a driver behind the growing threat from AMR and antibiotic-resistant bacteria.
“Finnish company Aidian has built up a leading, global position in point-of-care diagnostics. The company’s instruments and tests are a key part of meeting global health-related challenges. Together with the majority shareholder Nordstjernan we want to develop the company further, with the aim of continuing to build up a leading player in point-of-care diagnostics”, says Morten Borge, CEO of Ferd.
Earlier this year, the Swedish family-controlled investment company Nordstjernan announced that it had acquired 100 percent of the shares in Aidian. Ferd is now purchasing 33 percent of the shares, thus becoming a part-owner of Aidian.
“We are very pleased to have Ferd as a partner in Aidian’s further development and growth journey. Nordstjernan and Ferd share many similarities in that we are family-controlled companies that both apply a long-term approach to our investments. We both also see great potential in the healthcare sector”, says Peter Hofvenstam, CEO of Nordstjernan.
The parties have agreed not to disclose the conditions of the transaction.

Peter Hofvenstam
President and CEO
Nordstjernan AB
Questions will be answered by:
Stefan Stern, Head of Communications, Nordstjernan
Telephone: +46 70 636 74 17
E-mail: stefan.stern@nordstjernan.se
 
Nordstjernan is a family-controlled investment company whose business concept is to be an active owner that creates long-term value growth. More information about Nordstjernan can be found on www.nordstjernan.se.